ARSACS research published in Frontiers Journal

The research by Drs Alanna Watt and Anne Mckinney “Molecular identity and location influence Purkinje cell vulnerability in ARSACS mice”  has been published in the Frontiers Journal. At this time, only the abstract is available. The manuscript will be on...

“Charting the neurodevelopmental stage of ARSACS (NeurodevARSACS): A cross-species longitudinal characterization of the early molecular changes in the brain, CSF and blood” – Drs. Justin Wolter, Matthis Synofzik & David Mengel

It is well established in neurodegenerative diseases that early therapeutic intervention – ideally before neurodegenerative cascades begin to breakdown neuronal function – is key to the success of disease-modifying therapies. Yet we do not understand the...

“Évaluer l’efficacité d’un programme de réadaptation à domicile visant l’amélioration des atteintes motrices, de l’équilibre, de la mobilité, des chutes et des activités courantes chez les personnes atteintes d’ARSACS” – Dre Elise Duchesne

  L’ataxie récessive spastique de Charlevoix-Saguenay (ARSACS) est une maladie incurable caractérisée par plusieurs déficiences motrices progressives apparaissant dès l’enfance. Bien que les atteintes soient majeures, entraînant de grandes difficultés à marcher...

“Is ARSACS a Tauopathy?”- Dr. Paul Chapple

This is the continuation of the project. More specific details to come.   As an indication of the research, following is the description of last year work.  Currently we are looking carefully at sacsin’s interaction with cytoskeletal proteins and...

Invitation to the ARSACS International Symposium

Invitation to the 6th ARSACS International Symposium to be held on November 4th, 2021.   Keynote speaker Dr. Schmahmann from the Massachusetts General Hospital. Half-day virtual conferences, free registration, opened to all. See Program. Please do not hesitate to...